My Alcon | United States

This page is available in English. Select below for other countries.

Select another country

Systane iLux2 Logo

 

 

Do More for Your
MGD Patients

 

Systane® iLux²® is the all-in-one, portable device that can help eye care professionals evaluate and treat MGD via customizable heat and expression of the meibomian glands.

ilux2 systane device

stop watch icon

8-12 MIN TREATMENT1,2

target icon

12-MONTH EFFICACY

MGD eye imaging icon

  IMAGING USED FOR
  MEIBOGRAPHY

Meet Systane® iLux²®

 

Provide Fast and Lasting Treatment to Your MGD Patients

Look to the world’s first meibomian gland dysfunction (MGD) thermal pulsation system with imaging that can be used for meibography + gland treatment + HD video replay - all in the palm of your hand.

The Systane® iLux²® is a portable, hand held device designed to help eye care professionals evaluate and treat MGD. The meibomian gland imaging capabilities allow patients to see the condition of their glands, helping educate them on the need for treatment.

The Systane® iLux²® system allows you to target dysfunctional meibomian glands, improving signs and symptoms of MGD through customizable, localized heat and compression therapy. It delivers fast and efficacious treatment,1,2 while allowing patients to visualize their results post procedure through HD video replay.

Place the Systane® iLux²® in your space using Augmented Reality!

 

To access the experience, open ilux.myalcon.com/ecp/ on the desktop browser and scan the QR code using your mobile phone.

Ilux QR Code

Key Features

Systane® iLux ²® MGD Thermal Pulsation System device
Systane® iLux ²® MGD Thermal Pulsation System device
All-in-one, portable device

 

Systane® iLux MGD Thermal Pulsation System gives you personalized treatment with HD video replay and gland imaging.

 

Systane® iLux ²® eye imaging at work
Systane® iLux ²® eye imaging at work
Patient education

 

Systane® iLux²® can image meibomian glands to help patients understand and see the results after the procedure.

 

 

Woman touching her cheek and looking in the mirror
Woman touching her cheek and looking in the mirror
Fast and efficacious

 

Treatment of both eyes using the Systane® iLux²® takes approximately 8-12 minutes.1,2 A single treatment can result in an increase in meibomian gland secretion, improvement in tear film stability, and reduction in dry eye symptoms as early as one week and can last for up to 12 months.3,4

 

Smiling eye doctor holding Systane® iLux ²® device
Smiling eye doctor holding Systane® iLux ²® device
You’re always
in control

 

The Systane® iLux²® device lets you customize heat and expression treatments across each easy-to-visualize treatment zone, allowing you to target therapy where the patient needs it most.

Patient Outcomes

 

Take control of dry eye treatment with Systane® iLux and see the results

Significant improvements in symptoms after one week. Post-treatment Meibomian Gland Score (MGS) increased on average by 315% versus baseline4*

1 week efficacy

Increased average meibomian gland function by 300% at 4 weeks post-treatment, compared to baseline5**

4 week efficacy

Improved meibomian gland secretion score (MGS) by more than 17 points at 12 months after treatment3†

12 week efficacy

*(P<0.0001). In a prospective, open-label, multicenter study of patients ≥18 years with MGD (n=30).
**Measured at baseline, 2 weeks, and 4 weeks.
†Meibomian gland scores (0-45) measured using Meibomian Gland Evaluator to assess the 15 glands of the lower lid of each eye with a grade from 0-3.

Who Might Benefit Most from Treatment with Systane® iLux²®?

    IDEEL-SB Score

     

    Systane® iLux²® was shown to be non-inferior to LipiFlow^ over 12 months and maintained clinically significant improvements in signs and symptoms of MGD vs. baseline.3
    Graph showing change in symptoms of over 12 months of patients treated with Systane® iLux²® compared to that of those treated with LipiFlow

    Key Findings with Systane® iLux²®

    Alt text
    Alt text
    Alt text
    Alt text

    Prospective, randomized, parallel group, investigator masked, multi-center, 12-month follow-up study. 236 subjects with meibomian gland dysfunction.3

     

     

    *Impact of dry eye on every day life (IDEEL-SB) symptom bother score (with 20 questions).
    ^Trademarks are the property of their respective owners.

     

    Meibomian Gland Score

     

    Systane® iLux²® was demonstrated to be non-inferior to Lipiflow^ for meibomian gland function through 12 months (at all measurements, including 1, 3, 6, 9 months).
    Graph showing comparable Meibomian gland scores (MGS) of iLux and LipiFlow over a 12 month time period (scores at baseline, 2 weeks and 1, 3, 6, 9, and 12 month marks)

    †Meibomian gland scores (0-45) measured using Meibomian Gland Evaluator to assess the 15 glands of the lower lid of each eye with a grade from 0-3.
    ††Impact of dry eye on every day life (IDEEL - SB) symptom bother score (with 20 questions).
    ^Trademarks are the property of their respective owners.

    Summary

     

    Non-inferiority of iLux® to LipiFlow^ was demonstrated in change from Baseline MGD scores(95% LCL of the LSM difference >-0.5), and change in Baseline IDEEL-SB module score (95% UCL of the LSM difference <12)
    Alt text
    Alt text

    Prospective, randomized, parallel group, investigator-masked, multi-center 12-month follow-up study

     

    Alt text
    Alt text

    Follow-up visits at 2 weeks and 1, 3, 6, 9, and 12 months

     

    Alt text
    Alt text

    236 subjects with meibomian gland dysfunction

     

    †Meibomian gland scores (0-45) measured using Meibomian Gland Evaluator to assess the 15 glands of the lower lid of each eye with a grade from 0-3.
    ††Impact of dry eye on every day life (IDEEL - SB) symptom bother score (with 20 questions).
    ^Trademarks are the property of their respective owners.

    Meibomian Gland Procedures Are the Fastest Growing Part of the Dry Eye Market6

    approximately 44 million adults
    approximately 44 million adults

    Approximately 44 million adults have dry eye symptoms.

     

    86%
    86%

    86% have signs of Meibomian Gland Dysfunction (MGD).7

     

    approximately 80% of eye care professionals
    approximately 80% of eye care professionals

    Nearly 8 out of 10 doctors consider Dry Eye treatment as an opportunity to grow their practice.8*

     

     

    *n=233 U.S. ODs, MDs.

     

    Eye Care Practitioners Know They Need to Do More for Their MGD Patients—Systane® iLux²® Can Help You Do Just That.

    Man smiling into eye examination device
    Man smiling into eye examination device
    Your patients

     

    Use Systane® iLux²® meibomian gland imaging and HD video to help patients see and understand the need for in-office MGD treatment.

     

     

     

     

    Eye doctor talking to patient about exam results
    Eye doctor talking to patient about exam results
    Your practice

     

    An all-in-one, easy to use device with implementation support from Optometric consultants who can help you seamlessly integrate your device, leading to improved patient experience and retention.

     

    Doctor performing eye exam
    Doctor performing eye exam
    Your bottom line

     

    Introduce a new business model and a new treatment pathway that can add to your practice's bottom line.

     

     

     

     

    Introduction Tutorial

    Observe the step-by-step process of how to use the Systane® iLux²® on a live patient

     

    CONTACT US

    Continue Your Patients' Dry Eye Care with Systane®, the #1 Doctor Recommended Brand of Artificial Tears.9

     

    LEARN MORE ABOUT SYSTANE® EYE DROPS

     

    *vs. SYSTANE® BALANCE.

    Systane® Complete PF and Systane® Hydration PF product boxes

    Systane® iLux2®


    Important Product Information

      The Systane® iLux is indicated for the application of localized heat and pressure therapy in adult patients with meibomian gland dysfunction (MGD), which is associated with evaporative dry eye, and to capture/store digital images and video of the meibomian glands.

      Do NOT use the Systane® iLux in patients with the following conditions: Patients whose pupils have been pharmaceutically dilated; patients with ocular injury or trauma, chemical burns, or limbal stem cell deficiency (within prior 3 months); patients with active ocular herpes zoster or simplex of eye or eyelid or a history of these within prior 3 months; patients with cicatricial lid margin disease; patients with active ocular infection, active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months; patients with an ocular surface abnormality that may compromise corneal integrity; patients with lid surface abnormalities that affect lid function in either eye; patients with aphakia; or patients with permanent makeup or tattoos on their eyelids.

      Federal law restricts this device to sale by or on the order of a licensed healthcare practitioner.
       

      The Disposable may not fit all eyes, such as eyes with small palpebral fornices. Use of the Systane® iLux is NOT recommended in patients with the following conditions: moderate to severe allergic, vernal or giant papillary conjunctivitis; severe eyelid inflammation; systemic disease conditions that cause dry eye; in patients who are taking medications known to cause dryness; patients with punctal plugs, or patients who have undergone ocular surgery within prior 3 months.

      Potential adverse effects may occur because of the procedure. These effects include but are not limited to, the onset or increase in: eyelid/eye pain requiring discontinuation of the treatment procedure, eyelid irritation or inflammation, temporary reddening of the skin, ocular surface irritation or inflammation (e.g., corneal abrasion, conjunctival edema or conjunctival injection (hyperemia)), and ocular symptoms (e.g., burning, stinging, tearing, itching, discharge, redness, foreign body sensation, visual disturbance, sensitivity to light).

      Attention: Please refer to the User Manual for a complete list of contraindications, instructions for use, warnings and precautions for the Systane® iLux.

       

      MGD patients are already in your exam chair

       

      Be the hero they’re looking for

       

       

       

      CONTACT US

       

      References:

      1. Tauber J, Owen J, Bloomenstein M, Hovanesian J, Bullimore MA. Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial. Clin Ophthalmol. 2020;14:405-418.
      2. Alcon data on file, 2019.
      3. Wesley G, Bickle K, Downing J, et al. Comparison of Two Thermal Pulsation Systems in the Treatment of Meibomian Gland Dysfunction: A Randomized, Multicenter Study. Optom Vis Sci. 2022;99(4):323-332.
      4. Geffen, D. iLux Efficacy after One Week of Treatment. Poster presented at American Academy of Optometry, Academy at Home, October 2020.
      5. Hardten DR, Schanzlin JD, Dishler JG, et al. Comparison of a handheld infrared heating and compression device for treatment of meibomian gland dysfunction to a thermal pulsation device. Presented at the Annual Meeting of the American Society of Cataract and Refractive Surgery (ASCRS); April 13–17, 2018; Washington, D.C.
      6. MarketScope LLC. 2020 Dry Eye Products Report: A Global Market Analysis for 2019 to 2025. St. Louis, MO: MarketScope LLC; 2020.
      7. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clin­ic-based patient cohort: a retrospective study. Cornea. 2012;31:472-478.
      8. Alcon data on file, 2018.
      9. Based on IQVIA ProVoice Survey of General Practitioners, Eye Care Professionals and Pharmacists, 12 months ending December 31, 2021.